Effects of short-term propylthiouracil treatment on P wave duration and P wave dispersion in patients with overt hypertyroidism

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 6, 2007, Pages 376-379

  Katircibasi, M T ^a   Deniz, F ^a,c   Pamukcu, B ^a   Binici, S ^a   Atar, I ^b  

^a ETIMESGUT MILITARY HOSPITAL   (Turkey)

^b Isparta Military Hospital   (Turkey)

^c Ust Hava ^*  (Turkey)

Author keywords

Hyperthyroidism; p wave dispersion; p wave duration; Propylthiouracil treatment

Indexed keywords

ANTITHYROID AGENT; LIOTHYRONINE; PROPYLTHIOURACIL; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; HYPERTHYROIDISM; MALE; P WAVE; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; THYROID HORMONE BLOOD LEVEL; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; ANTITHYROID AGENTS; ATRIAL FIBRILLATION; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; PROPYLTHIOURACIL; THYROID HORMONES;

EID: 34347228662     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-971066     Document Type: Article

References (16)

1. Klein I, Ojamaa K. Thyrotoxicosis and the heart. Endocrinol Metab Clin North Am 1998; 27: 51-62
2. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of "idiopathic" atrial fibrillation. Am J Cardiol 1979; 44: 9-12
3. Gilligan DM, Ellenbogen KA, Epstein AE. The management of atrial fibrillation. Am J Med 1996; 101: 413-421
4. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Eng J Med 1994; 331: 1249-1252
5. Dilaveris PE, Gialafos EJ, Sideris SK, Theopistou AM, Andrikopoulos GK, Kyriakidis M, Gialafos JE, Toutouzas PK. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998; 135: 733-738
6. Aytemir K, Ozer N, Atalar E, Sade E, Aksoyek S, Ovunc K, Acil T, Nazli N, Ozmen F, Oto A, Kes S. P-wave dispersion on 12-lead electrocardiogram in patients with paroxysmal atrial fibrillation. Pacing Clinical Electrophysiology 2000; 23: 1109-1112
7. Steinberg JS, Zelenkofske S, Wong SC, Gelernt M, Sciacca R, Menchavez E. Value of P wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. Circulation 1993; 88: 1622-2618
8. Dilaveris PE, Gialafos EJ, Andrikopoulos GK, Richter DJ, Papanikolaou V, Poralis K, Gialafos JE. Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clinical Electrophysiology 2000; 23: 352-358
9. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509
10. Ma ML, Watanabe K, Watanabe H, Hosaka Y, Komura S, Aizawa Y, Yamamoto T. Different gene expression of potassium channels by thyroid hormone and an antithyroid drug between the atrium and ventricle of rats. Jpn Heart J 2003; 44: 101-110
11. Nakazawa HK, Sakurai K, Hamada N, Momotani N, Ito K. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72: 903-906
12. Moe GK, Abildskov JA. Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. Am Heart J 1959; 58: 59-70
13. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62: 395-410
14. Cetinarslan B, Akkoyun M, Canturk Z, Tarkun I, Kahranman G, Komsuoglu B. Duration of the P wave and P wave dispersion in subclinical hyperthyroidism. Endocr Pract 2003; 9: 200-203
15. Aras D, Maden O, Ozdemir O, Aras S, Topaloglu S, Yetkin E, Demir AD, Soylu MO, Erdogan MF, Kisacik HL, Korkmaz S. Simple electrocardiographic markers for the prediction of paroxysmal atrial fibrillation in hyperthyroidism. Int J Cardiol 2005; 99: 59-64
16. Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905-917